MedTrace Logo

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

NCT01387815 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 662

Last updated 2019-12-05

Study results available
· View outcomes & findings →

Summary

This was a Canadian post-marketing observational study (PMOS) utilizing a prospective cohort design that compared the real - life effectiveness of adalimumab to topical and traditional systemic agents in the management of psoriasis and its impact on the patient's quality of life and societal burden of illness.

Conditions

Interventions

BIOLOGICAL

Adalimumab

Adalimumab administered by subcutaneous injection.

Sponsors & Collaborators

  • Cato Research

    collaborator INDUSTRY

  • JSS Medical Research Inc.

    collaborator INDUSTRY

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-16
Primary Completion
2018-06-29
Completion
2018-06-29
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01387815 on ClinicalTrials.gov